70 results about "Endogenous metabolism" patented technology

The CEST effect for various neurotransmitters and energy metabolites in the brain and muscles and various endogenous metabolites in the liver, brain, and myocardium are imaged using MR imaging to illustrate a unique CEST effect that may be used to monitor the concentration of the metabolite and hence to characterize and monitor various disease states in the body correlated to the concentration of that metabolite. By adjusting the timing, amplitude, and length of the RF pulse as well as other parameters of the CEST pulse sequence to address the unique chemical shifts and exchange rates of the target, new targets with unique characteristics may be acquired using CEST MR imaging.

The present invention relates to novel compounds and formulations thereof which compounds are ligands, e.g., agonists or antagonists, for a metabotropic glutamate receptor or a NAALADase enzyme or both. The present invention also relates to methods of modulating the activity of a metabotropic glutamate receptor or a NAALADase enzyme or both, e.g., in a subject in need thereof, using a compound or formulation of the present invention. The present invention also relates to methods of treating a subject suffering from a chronic or acute disease, malady or condition due at least in part to an abnormality in the activity of an endogenous metabotropic glutamate receptor or a NAALADase enzyme or both, using a compound or formulation of the present invention.

The present invention relates to novel compounds and formulations thereof which compounds are ligands, e.g., agonists or antagonists, for a metabotropic glutamate receptor or a NAALADase enzyme or both. The present invention also relates to methods of modulating the activity of a metabotropic glutamate receptor or a NAALADase enzyme or both, e.g., in a subject in need thereof, using a compound or formulation of the present invention. The present invention also relates to methods of treating a subject suffering from a chronic or acute disease, malady or condition due at least in part to an abnormality in the activity of an endogenous metabotropic glutamate receptor or a NAALADase enzyme or both, using a compound or formulation of the present invention.

The invention provides a method for evaluating the quality of a Chinese patent medicament by using metabonomics. The method comprises the following steps: 1) according to the indication of traditional Chinese medicines, establishing a corresponding animal model and screening; 2) taking various of samples of the traditional Chinese medicines, and intervening a disease model animal by a corresponding route of administration; 3) collecting a corresponding biological sample and acquiring the metabolism finger-print of the sample; 4) carrying out pattern recognition on the metabolism fingerprints of a normal group and a disease group to obtain a metabolism biomarker group; 5) calculating the similarity of the metabolism biomarker group and the normal group in different administration groups, or carrying out PLS (partial least squares) regression analysis on differential endogenous metabolites, and observing the influence of medicament treatment on the endogenous metabolites; and 6) according to the similarity result or the result of the PLS regression analysis, evaluating the medicaments, wherein the more normal the control group trends to be, the better efficacy of the medicament is.

The invention provides a traditional Chinese medicine pharmacokinetics-pharmacodynamics combined analysis method, which determines various endogenous metabolites in blood samples of a blank control group, a model group and a model treatment group by a GC-MS method, uses an abnormally-changed metabolite group of the model group as a biomarker group, uses an effect index with obvious callback of the abnormally-changed metabolite group after traditional Chinese medicine intervention as an efficacy marker group, determines the contents of various drugs in the blood samples of a model animal after single dose by a LC-MS method, draws a plasma concentration-time curve, calculates the pharmacokinetic parameters of each component; determines the amount of the endogenous efficacy marker group in the blood samples of the model animal single dose group by a GC-MS method, draws a time-effect curve, performs PK-PD combined analysis by combining with the plasma concentration-time curve and parameters. The invention reveals the efficacy substance base of traditional Chinese medicine in the treatment of cardiovascular diseases, and provides an effective method for traditional Chinese medicine pharmacokinetics-pharmacodynamics combined analysis.

The invention discloses a test method for characterizing the biological effects of smoke exposure based on metabolomics. The test method adopts the metabolomics analysis method, and the biomarker groups related to the biological effects of smoke exposure are tested in different drug administration groups. The changes between groups are used to characterize the biological responses of experimental animals placed in the smoke exposure environment. The present invention is easy to operate, and evaluates the influence of mainstream smoke on endogenous metabolites in rats, and compares the similarities and differences between the effects of natural herbal added tobacco and ordinary cigarettes on endogenous metabolites, in order to evaluate the harm reduction effect of cigarettes and its associated mechanisms provide a reliable tool.

The invention discloses a method for identifying the varieties of dendrobium huoshanense and dendrobium officinale based on metabonomics. The method comprises the following specific steps: (1) collecting dendrobium samples; (2) preparing dendrobium metabonomics samples; (3) detecting metabolites of the dendrobium samples; and (4) performing metabonomics data processing and analysis. The method provided by the invention has the following advantages: a lot of endogenous metabolite information of dendrobium is acquired by means of metabonomics; among the endogenous metabolites, the characteristic metabolites for identification of dendrobium huoshanense and dendrobium officinale are selected out, and then such two dendrobium varieties are distinguished from each other on the whole; the technical mode is advanced and the experimental result is reliable; and a good means is provided for dendrobium variety identification and dendrobium quality assessment.

The invention relates to a method for evaluating and predicating the toxicity and the efficacy of a medicament based on an endogenous metabolism signal which is acquired by eliminating an exogenous metabolism signal in a biological sample, in particular to the method for evaluating and predicating the specific toxicity and the non-specific toxicity of the medicament by using a metabonomic technology. In the method, the biological sample depended by a metabolism group is obtained according to a blank control group, a model toxic substance group and a toxicity test group which are set in the metabolism group; and a sample measuring signal matrix is detected and acquired for evaluating and predicating the toxicity of the medicament. The invention simultaneously discloses a method for evaluating and predicating the efficacy by using the metabonomic technology. In the method, a biological sample depended by the met toxic substance group, a treatment group and a positive medicament control group which are set in the metabolism group; and a sample measuring signal matrix is detected and acquired for evaluating and predicating the efficacy of the medicament. According to the methods disclosed by the invention, the toxicity and the efficacy of the medicament can be evaluated more comprehensively and accurately.

A method for producing a rose characterized by artificially suppressing the rose endogenous metabolic pathway and expressing the pansy gene coding for flavonoid 3′,5′-hydroxylase.

The invention discloses a method for testing a curative effect of a Chinese medicine Zhibai Dihuang pill based on application of metabonomics. The method comprises the following steps: dividing experimental animals into a control group, a diabetic nephropathy model group and a diabetic nephropathy administration group, injecting the experimental animals and collecting tissue samples of urine, serum and kidney; fixing the renal tissues of the three groups of rats through 10% neutral formalin, carrying out paraffin embedding, slicing and flaking the renal tissues, staining the renal tissues through routine hematoxylin-eosin and observing the pathological changes of the renal tissues under an optical microscope; measuring the chemical indexes and detecting the histopathology of the serum samples and the urine samples; preparing tissue samples of urine, serum and kidney, and obtaining data of a 1H NMR (Nuclear Magnetic Resonance) spectrum; carrying out NMR data processing and pattern recognition analysis through a statistical method; and comparing and analyzing important physiological and biochemical indexes of different groups of rats. The method disclosed by the invention can be used for obtaining the information of a large amount of endogenous metabolites of an organism through a metabonomics technology and screening metabolite changes caused by effective ingredients in the Zhibai Dihuang pill.

The invention discloses a use of endogenous metabolites as markers for predicting the prognosis risk of coronary heart disease or in preparation of a kit for predicting the prognosis risk of coronaryheart disease. The metabolite marker can effectively predict the risk of death and major adverse cardiovascular events (MACE) in patients with coronary heart disease and the risk of cardiac insufficiency, and has the characteristics of specificity, sensitivity, high efficiency and non-invasiveness. After the metabolite marker is used for predicting the prognosis survival rate of patients with coronary heart disease, the AUC is 65% or more. Through combination, the AUC is close to 100% compared with AUC based on the single marker and the prediction effect is good. The method for detecting through the marker has high sensitivity, is convenient and quick and produces accurate and reliable results. The predictive model constructed by the marker can be used for predicting the prognosis risk ofcoronary heart disease, has good predictive effects and high sensitivity, is convenient, rapid and non-invasive and has an important clinical application value.

The invention belongs to the technical field of model establishment and evaluation methods with an aim to solve problems about low flexibility and poor accuracy in an existing model establishment andevaluation method for the nephritic syndrome rats and provides a model establishment and evaluation method for the nephritic syndrome rats. Changes of endogenous metabolites in the urine of terminal products are analyzed by metabolomics, all 1 HNMR spectra are processed through MestReNova software to acquire integral data, statistical analysis of the content of 12 biomarkers is combined with, thechanges of the mean value of the 12 biomarkers in the urine before and after modeling reflect the change trend of the urine metabolite content in the nephritic syndrome rats, and models of nephritic syndrome are evaluated in a targeted manner. Dynamic body contours before and after modeling is reflected comprehensively, flexibly and systematically, rationality and scientific nature of model reproduction are comprehensively reflected, the reliable evaluation method for new drug development and pharmacological research is provided, and the method is efficient, rapid, noninvasive and high in specificity.

The invention belongs to the technical field of model building and evaluating methods, particularly relates to a building and evaluating method of a chronic atrophic gastritis rat model and mainly solves the technical problem that existing building and evaluating methods of the chronic atrophic gastritis rat model are low in accuracy, high in cost and time consuming and labor consuming. Technology of metabonomics is adopted, and a metabolic profile dynamic trajectory spectrum is acquired by analyzing changes in endogenous metabolite in organism end product urine before and after model building. In addition, MestReNova software is used to process all NR spectra to obtain integral data, statistical analysis on content of 18 biomarkers is combined, and a rule that changes in integral average value of the 18 biomarkers in the urine before and after model building reflect changing tendency of urine metabolic trajectory of rats with chronic atrophic gastritis to certain extent is found, so that the chronic atrophic gastritis model is evaluated in a targeted manner.

The invention discloses a disease prediction method and system based on medical big data. The method comprises the following steps: importing mass spectrum data of mainstream mass spectrum instrumentmanufacturers, and completing the conversion from original mass spectrum data of the manufacturers to a general data format; realizing automatic labeling and qualitative analysis of endogenous compounds in the mass spectrum through a metabolite compound database according to the spectrum information of the endogenous metabolites of the individual human body and a compound search matching algorithm; wherein the loading is used for effectively managing huge and complex human body metabonomics samples and carrying out data mining and modeling, and the loaded data types mainly comprise targeted and non-targeted metabonomics mass spectrum original data and labeling results; performing standardized cleaning, compound alignment and qualitative and quantitative analysis on complex multi-sample data, and performing correction by adopting a multi-class algorithm; and adopting a machine learning model training set algorithm with different types of mass spectrum data processing characteristics tocomplete the whole process of training, publishing and maintaining the user disease prediction model.

The invention relates to a drug screening cell model with NLRP3 (NLR family, pyrin domain containing 3) as a target spot and an application of the drug screening cell model. According to the cell model, a mammalian cell is used as a host, a recombinant plasmid containing an NLRP3 3'-UTR (untranslated region) core sequence and a reporter gene is transfected, and the NLRP3 3'-UTR core sequence is one of SEQ ID 1-9. According to the cell model, the minimum 3'-UTR sequence which can substitute for the NLRP3 mRNA (messenger ribonucleic acid) overall length is found with a 3'-UTR fragment reduction method, the sequence is connected with the reporter gene, and then the connected recombinant plasmid is transfected into an HCT116 cell strain to form a stable-expression cell strain, then endogenous metabolite and natural compounds to be screened are added, the expression level of the reporter gene is determined, and meanwhile, positive and negative control groups are established, so that the activity of substances to be screened are evaluated, and a sensitive and effective natural innovative drug screening method applicable to high-flux anti-infective drugs is provided.

The invention discloses a method for screening myocardial ischemia resisting pharmacodynamic material basis of yang exhaustion treating decoction. The method comprises the following steps: 1, determining myocardial ischemia resisting endogenous metabolin of the yang exhaustion treating decoction and measuring the peak area; 2, determining in-vivo migration constituents in the yang exhaustion treating decoction and measuring the peak area; 3, performing correlation analysis on the peak area of the myocardial ischemia resisting endogenous metabolin of the yang exhaustion treating decoction and the peak area of the in-vivo migration constituents in the yang exhaustion treating decoction and screening out myocardial ischemia resisting pharmacodynamic material basis of the yang exhaustion treating decoction. The method disclosed by the invention is based on isoproterenol-induced rat myocardial ischemia model; an ultrahigh performance liquid chromatography-quadrupole rod-flight time mass spectrum non-targeted metabonomic technology and a targeted metabonomic technology based on an ultrahigh performance liquid chromatography-triple quadrupole rod mass spectrum are utilized to screen out 12 kinds of myocardial ischemia resisting pharmacodynamic material basis of the yang exhaustion treating decoction; thus, accuracy of the myocardial ischemia resisting pharmacodynamic material basis ofthe yang exhaustion treating decoction is improved, a screening period is shortened, and screening consumption cost is reduced.

The invention discloses an endogenous metabolic small molecular marker for indicating a healthy aging key pathway and application. The number of the endogenous metabolic small molecules is 155. The key pathway is totally 30. The invention provides a new endogenous small molecule marker for indicating the key pathways for blood health and aging for the first time, and the change of the small molecules can be measured to comprehensively evaluate the change of pathways related to health and aging in a human body, thereby providing support for subsequent intervention and response.

The invention discloses an early liver cancer rat model construction and evaluation method, and belongs to the technical field of model construction and evaluation methods. The scheme of the inventionmainly solves the problems of poor accuracy, low sensitivity, time waste and energy waste of a current early liver cancer rat model construction and evaluation method. The scheme of the invention adopts a metabonomics technology, and analyzes changes in endogenous metabolites in urine, the end product of the body before and after modeling, to obtain a dynamic trajectory map of the metabolic profile of the pathological process. In addition, all nuclear magnetic resonance spectrums are processed by using MestReNova software to obtain integral data, the content of 19 biomarkers is combined for statistical analysis, and results show that the change of the integral mean value of the 19 biomarkers in the urine before and after modeling reflects the change trend of the urine metabolic process ofrats with liver cancer. The method of the invention provides a detection method that is simple to obtain specimens, and is more economical, safe and effective, and provides a high-sensitivity, high-throughput, non-invasive, and highly-specific evaluation method for new drug research and development and pharmacological research.

The invention discloses a metabolism transformation Bacillus subtilis biotransformed cell. The preparation method comprises: carrying out recombinant over-expression to obtain a L-glutamic acid oxidase, carrying out metabolism engineering transformation on the endogenous glutamic acid decomposition pathway of Bacillus subtilis, and finally transforming the glutamic acid transport pathway of Bacillus subtilis to prepare the Bacillus subtilis biotransformed cell, ie., the recombinant Bacillus subtilis. According to the present invention, the experimental basis is provided for the construction and the improvement of the whole cell transformation system involved in cellular endogenous metabolism, and the reference is provided for the production of alpha-ketoglutaric acid through the efficient whole cell transformation of L-glutamic acid with Bacillus subtilis.

The invention discloses a cold-coagulation-blood-stasis-syndrome-resistant differential metabolite metabolic pathway and study method of a Chinese angelica-based cold-coagulation blood-stasis treatment decoction. The method comprises: detecting and analyzing endogenous metabolites changed at different time points after cold-coagulation blood-stasis symptoms forming of a female rat under an ice-water bath and epinephrine induction and Chinese angelica-based cold-coagulation blood-stasis treatment decoction intervention by using an ultra-high performance liquid chromatography tandem mass spectrometry so as to obtain a fingerprint spectrum; with a multivariate variable statistical analysis method, carrying out screening from a plurality of variables and identifying 21 significantly changed metabolites; and enriching eight metabolic pathways related to different development stages of the cold-coagulation blood-stasis symptom by using ametaboanalyst open-source online metabonomics analysiswebsite. According to the invention, the related metabolic changes in the occurrence and development process of the old-coagulation blood-stasis symptoms and the treatment process of the Chinese angelica-based cold-coagulation blood-stasis treatment decoction are studied by using a dynamic analysis method; the disease occurrence and development mechanisms at different time points can be revealed;and the abnormal metabolic network regulated and controlled by medicines in the treatment process can be clarified.

The invention discloses a determination method of the potency of a traditional Chinese medicine zedoary turmeric oil by using metabolomics. The method comprises the steps that: an unilateral ureteral obstruction induced renal interstitial fibrosis model is adopted, an animal modeling is carried out; processing and sampling are carried out after animal modeling is carried out for 3 days, 7 days, 14 days, 21 days, and 28 days; animal kidney tissues are fetched; kidney tissue pathological changes are observed by using an optical microscope; serum samples are prepared, and 1H NMR spectral data is obtained; NMR data processing and pattern recognition analysis are carried out; and analysis is carried out by using SPSS13.0 software. According to the invention, information of large amount of endogenous metabolites in bodies can be obtained with the metabolomic technology, and metabolite changes of potencies of various effective components in zedoary turmeric oil upon various targets can be screened. Therefore, the potency of zedoary turmeric oil can be comprehensively evaluated. The invention provides an excellent method for evaluating zedoary turmeric oil potency.

The invention relates to a resting preservation method of a liquid strain in an edible fungus, which belongs to the technical field of application of liquid strains in edible funguses. The method comprises the following steps: the prepared liquid strain in the edible fungus is centrifuged or filtered to collect a mycelium pellet, then the mycelium pellet is washed for 1-4 times with cleaning buffer solution, then the mycelium pellet is collected centrifugally or in a filtering manner, and the mycelium pellet is suspended in a resting culture medium for culture for 6-24 hours and then is preserved by cold storage. Due to the adoption of the preservation method, a strain cell in the mycelium pellet can be kept in a resting state, the faint endogenous metabolism is only carried out, the strain cell cannot divide, and the strain can keep lasting vitality, therefore, the liquid strain in the edible fungus, which is prepared by one-time fermentation, can be prepared for a long term, the storage conditions of the liquid strain in the edible fungus are improved, and the utilization level of the liquid strain in the edible fungus is improved.

The invention belongs to the technical field of biological analysis and detection, and relates to an ion strength virtual correction and quantitative mass spectrum imaging analysis method of drugs, which can be used for exploring the accurate content of drug molecules at different spatial positions in a living body. According to the method, isotope labeled drugs are not needed to be used as internal standards, endogenous metabolite ions of each mass spectrum image acquisition pixel point are used as natural internal standards, a multiple regression prediction model of the endogenous metaboliteions-drug relative matrix effect is established, virtual correction of the biological tissue specific matrix effect is achieved, and quantitative calculation of drug content in any area in a whole biological tissue sample is completed through a standard curve established by a standard reference sample. The invention provides an intuitive and visual quantitative imaging method for quickly acquiring absorption, distribution, metabolism and excretion information of candidate drugs in a body, predicting potential toxic and side effects and the like.

The invention discloses a method for identifying metabolic markers based on heart Yang deficiency syndrome of coronary heart diseases. The method solves the problem that the existing clinical diagnosis method of heart Yang deficiency syndrome of coronary heart diseases has poor sensitivity so that the relationship between ingredients in the formula and curative effects is difficult to recover. Themethod comprises 1, carrying out UPLC analysis on n healthy subjects and n patient subjects suffering from heart Yang deficiency syndrome of coronary heart diseases through a UPLC-G2-Si-HDMS method to determine endogenous metabolites in serum samples, 2, carrying out full scanning on the endogenous metabolites in a positive and negative ion mode through a G2-Si-HDMS method to determine endogenousmetabolite structures and 3, identifying blood metabolic biomarkers of subjects suffering from heart Yang deficiency syndrome of coronary heart diseases. The method is used in the field of metabolicmarker identification.

The present invention relates to a method and system for dynamically analyzing, determining, predicting and displaying ranked suitable heterologous biosynthesis pathways for a specified host. The present invention addresses the problem of finding suitable pathways for the endogenous metabolism of a host organism because the efficacy of heterologous biosynthesis is affected by competing endogenous pathways. The present invention is called MRE (Metabolic Route Explorer), and it was conceived and developed to systematically and dynamically search for, determine, analyze, and display promising heterologous pathways while considering competing endogenous reactions in a given host organism.

The invention discloses an anti-static polyvinyl alcohol fruit and vegetable fresh-keeping film. The anti-static polyvinyl alcohol fruit and vegetable fresh-keeping film is characterized by being prepared from the following raw materials: appropriate amounts of camellia seed, mint leaf, rhizoma zingiberis, pine twig, clove, acetone, anhydrous sodium sulfate, zeolite, sodium nitrate solution, silver nitrate solution, sodium hexametaphosphate, hydroxyethyl acrylate, acrylic acid, absolute ethyl alcohol, azodiisobutyronitrile, lauryl mercaptan, polyvinyl alcohol, vinyl acetate, ammonium persulfate solution, octadecyl imidazoline, fatty alcohol-polyoxyethylene ether, dodecyl potassium phosphate, and deionized water. The anti-static polyvinyl alcohol fruit and vegetable fresh-keeping film of the invention is good in mechanical performance, stable in structure, good in air permeability, and good in antibacterial action, and can slow down endogenous metabolism aging of fruits and vegetables and spoilage caused by exogenous microorganisms, thus greatly prolonging the length for preservation and effectively keeping the quality of the fruits and vegetables.

The present invention relates to novel compounds and formulations thereof which compounds are ligands, e.g., agonists or antagonists, for a metabotropic glutamate receptor or a NAALADase enzyme or both. The present invention also relates to methods of modulating the activity of a metabotropic glutamate receptor or a NAALADase enzyme or both, e.g., in a subject in need thereof, using a compound or formulation of the present invention. The present invention also relates to methods of treating a subject suffering from a chronic or acute disease, malady or condition due at least in part to an abnormality in the activity of an endogenous metabotropic glutamate receptor or a NAALADase enzyme or both, using a compound or formulation of the present invention.

Described herein are systems and methods for image-based (e.g., MRI-based) spatial and temporal mapping of macrophages and other cell types, without the need for image contrast agents. These systems and methods are particularly useful for imaging macrophages because they naturally store metabolites, such as iron. Alternatively, the systems and methods described herein can be used where contrast agents are administered, rather than looking only at endogenous metabolite deposits.

The invention belongs to the technical field of evaluation methods of models, and particularly relates to construction and evaluation methods of a blood deficiency mouse model. The construction and evaluation methods mainly solve the technical problems that an existing evaluation method of a blood deficiency model is low in precision and poor in specificity. According to the construction and evaluation methods of the blood deficiency model, a metabonomic technology is adopted, the change of endogenous metabolites in the spleen organs of mice of a blank control group and a model group is analyzed, all mass spectrum spectrograms are processed through CD software to obtain integral data, then in combination with the content of 15 biomarkers, statistical analysis is made to the integral mean value change tendency of biomarkers in the spleen organs of the mice of the blank control group and the model group, so that the change tendency of the content of the metabolites of the spleen organs of the blood deficiency mice is obtained, and thus the blood deficiency mouse model is evaluated with pertinence. By means of the construction and evaluation methods, the rationality and scientificityof model replication are reflected, the profiles of mouse bodies of the blank control group and the model group are systematically and comprehensively shown, the methods have the advantages of being comprehensive, systematic, efficient and high in specificity, and a reliable evaluation method is provided for new drug research and development and pharmacological research.